OR WAIT null SECS
The expansion will feature added capabilities for formulation development via the upgrade of drug product development laboratories and the addition of Gerteis roller compaction equipment for dry granulation processing.
Lonza announced on Nov. 18, 2020 that it is expanding its highly potent API (HPAPI) drug product development and manufacturing capabilities at its Tampa, FL site.
According to a company press release, the expansion will feature added capabilities for formulation development via the upgrade of drug product development laboratories and the addition of Gerteis roller compaction equipment for dry granulation processing.
"Our customers look to Lonza to meet their challenge of accelerating timelines to clinic and market. In response, we strive for seamless service provision across our drug substance and drug product development and manufacturing network,” said Christian Dowdeswell, vice-president and global head of Commercial Development, Small Molecules, Lonza, in the press release. “These new investments ensure that we have capabilities that meet our customers' needs and standardizes state-of-the-art continuous dry granulation across Lonza's solid oral dose manufacturing network. This gives us more flexibility in development as well as facilitating more rapid scale-up."
"The ability to safely and efficiently handle HPAPI is increasingly critical to effectively partner with our customers, especially those focused on cancer therapies,” added Robert Beland, Managing Director, Lonza Tampa, in the press release. “The new roller compactor complements the capabilities of both the Tampa site and our overall network for product development and manufacturing based on HPAPI."